UA138155U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination and radiography. Additionally, in the patient's serum determine the polymorphism of the nitric oxide synthase gene (eNOS T786C), the content of thrombomodulin, folic acid, oxyproline, homocysteine and with homozygous carrier 786-CC, thrombomodulin levels, 6 ng / ml / 5 ml / ml / ml 15 μmol / l, homocysteine> 20 μmol / l predict the development of osteoarthritis.

Description

A useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - T. 2. - E. 186-196). The disadvantage of these methods is the inability to predict the dynamics of the process in the early subclinical stages, the inability to prevent its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, according to a useful model, the polymorphism of the nitric oxide synthase gene (EMO5 T786C), the content of thrombomodulin, folic acid, oxyproline, homocysteine, and in case of homozygous carrier 786-SS are determined in the patient's blood serum. levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, oxyproline 215 μmol/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, X-rays are taken, the eMO5 1786C gene polymorphism is determined, the content of thrombomodulin, folic acid, oxyproline, and homocysteine is determined by the immunoenzymatic method. With homozygous carrier 786-SS and levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, oxyproline 15 μmol/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

A specific example of using the method

Patient D., 68 years old, was hospitalized in the clinic due to pain syndrome in the right hip joint. Examined, x-ray taken. No signs of osteoarthritis were found. The eMOo5 1786C gene polymorphism and the content of thrombomodulin, folic acid, oxyproline, and homocysteine were determined in the serum. A homozygous carrier of 786-SS was established, the levels of thrombomodulin - 15 ng/ml, folic acid - 3.2 ng/ml, oxyproline - 29 μmol/l, homocysteine - 33 μmol/l. The development of osteoarthritis was diagnosed. After 11 months, X-rays showed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing development

From osteoarthritis in the early stages.

Claims (1)

USEFUL MODEL FORMULA A method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that the polymorphism of the nitric oxide synthase gene (6ЕМО5 17860), the content of thrombomodulin, folic acid, oxyproline, homocysteine, and in the case of homozygous carrier 786-СС, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, oxyproline 215 μmol/l, homocysteine 220 μmol/l predict the development of osteoarthritis.